CGRP — calcitonin gene-related peptide — is the migraine target that opened the modern migraine therapeutics market (erenumab, fremanezumab, galcanezumab, and the gepant small molecules). Coverage on this site has shifted recently as GLP-1 drugs have shown migraine benefit in head-to-head and registry analyses.
The most cited 2026 read: AAN 2026 reported that GLP-1 agonists cut migraine ED visits 10% and hospitalizations 14% versus topiramate in a 22,000-patient comparative study, plus a 42% reduction in CGRP monoclonal antibody starts. The overlap raises questions about whether GLP-1s, gepants, and CGRP antibodies sit in additive or competitive positions for chronic migraine.
Stories here cover the migraine peptide pipeline and the GLP-1 spillover. See #migraine for the indication and #gepants for small-molecule CGRP antagonists.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
New data shows the first oral CGRP antagonist ubrogepant demonstrates better efficacy when administered during mild pain rather than waiting for moderate-to-severe migraine pain.
Retrospective study found combining CGRP monoclonal antibodies with gepants is a safe and well-tolerated dual-mechanism migraine prevention approach.
Retrospective cohort study showed significant migraine frequency reduction with favorable safety for patients with comorbid MS taking CGRP-targeted treatments.